Lilly Selects ICON to Manage its Clinical Data Management Business Outside the US
18 Novembre 2008 - 12:10PM
Business Wire
ICON plc (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of
outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has signed an agreement with Eli Lilly and Company (NYSE: LLY)
to manage the company�s clinical data management business outside
the United States. The agreement, which spans more than three dozen
countries, excluding the United States and Japan, will help to
transform Lilly�s research and development organisation as they
seek to drive productivity, gain speed to market and lower drug
development costs. �Today�s announcement is a significant milestone
in the relationship between ICON and Lilly,� commented Peter Gray,
CEO at ICON. �We have been working together in an innovative
partnership approach to the outsourcing relationship, and the
decision to move this important business function to ICON is based
on our proven ability to meet project deadlines whilst driving
process efficiencies. We look forward to building on this
initiative and to helping Lilly realise its vision of a networked
business model.� "Lilly is eager to leverage ICON�s substantial,
scalable clinical data management capabilities around the globe.
Through this agreement, we take another significant step in our
ongoing agenda to increase flexibility, reduce fixed cost, and
focus internal resources on core capabilities,� said Jeff Kasher,
Lilly�s Vice President and Chief Operating Officer of Global
Clinical Development. About ICON plc ICON plc is a global provider
of outsourced development services to the pharmaceutical,
biotechnology and medical device industries. The Company
specializes in the strategic development, management and analysis
of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. ICON teams have
successfully conducted over 5,500 development projects and
consultancy engagements across all major therapeutic areas. ICON
currently has over 6,600 employees, operating from 71 locations in
38 countries. Further information is available at www.iconplc.com.
About Lilly Lilly, a leading innovation-driven corporation, is
developing a growing portfolio of first-in-class and best-in-class
pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent
scientific organizations. Headquartered in Indianapolis, Ind.,
Lilly provides answers � through medicines and information � for
some of the world's most urgent medical needs. ICON/ICLR-G
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024